GlassScriptPhysician profile
Sarah Malsch
NPI 1619434057
$3,525.44
in general payments reported to CMS, 2019-2025
22 companies · $854 in 2025
The $854 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.92 · 2022: $891 · 2023: $1,343 · 2024: $344 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830 · Travel and Lodging: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.60 |
| Travel and Lodging | $712.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,092.89 | 2022-2025 | Micra, Linq II |
| Boston Scientific Corporation | $449.33 | 2022-2024 | Zoom Wireless Transmitter, Watchman Flx, Resonate El Icd Vr |
| Amgen INC. | $386.26 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $303.43 | 2021-2025 | |
| Pfizer INC. | $229.08 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $152.91 | 2022-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.38 | 2021-2025 | Jardiance |
| Chiesi USA, INC. | $130.29 | 2025 | Kengreal |
| Esperion Therapeutics, INC. | $119.36 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.04 | 2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $55.47 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $51.83 | 2022-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $51.73 | 2023-2024 | Uptravi |
| Cvrx, INC. | $49.01 | 2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $45.04 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.84 | 2022-2025 | |
| Abiomed | $39.90 | 2024 | Impella |
| Novo Nordisk INC | $29.12 | 2023 | |
| Abbott Laboratories | $28.15 | 2024 | Jot Dx, Cardiomems |
| Glaxosmithkline, LLC. | $19.52 | 2025 | Shingrix, Arexvy |
| Bridgebio Pharma, INC. | $16.24 | 2025 | Attruby |
| Terumo Medical Corporation | $14.62 | 2023 | Angio-Seal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Malsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.